New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 21  •  04:00PM ET
33.57
Dollar change
-0.37
Percentage change
-1.09
%
Index- P/E- EPS (ttm)-0.41 Insider Own0.76% Shs Outstand50.37M Perf Week5.83%
Market Cap1.69B Forward P/E- EPS next Y-1.19 Insider Trans-26.07% Shs Float49.99M Perf Month0.96%
Enterprise Value1.24B PEG- EPS next Q-0.24 Inst Own96.39% Short Float16.72% Perf Quarter-6.88%
Income-20.10M P/S4.73 EPS this Y32.22% Inst Trans5.72% Short Ratio26.89 Perf Half Y13.72%
Sales357.71M P/B4.38 EPS next Y-71.55% ROA-1.91% Short Interest8.36M Perf YTD13.80%
Book/sh7.67 P/C1.92 EPS next 5Y-11.99% ROE-5.38% 52W High39.33 -14.64% Perf Year-0.53%
Cash/sh17.53 P/FCF58.98 EPS past 3/5Y37.84% 20.08% ROIC-2.44% 52W Low23.15 45.01% Perf 3Y-30.61%
Dividend Est.- EV/EBITDA- Sales past 3/5Y104.15% 56.79% Gross Margin98.18% Volatility4.34% 4.22% Perf 5Y-
Dividend TTM- EV/Sales3.48 EPS Y/Y TTM62.72% Oper. Margin-13.01% ATR (14)1.40 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.86 Sales Y/Y TTM26.90% Profit Margin-5.62% RSI (14)48.32 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio5.89 EPS Q/Q10.88% SMA20-1.25% Beta0.80 Target Price62.68
Payout- Debt/Eq1.12 Sales Q/Q31.32% SMA50-0.83% Rel Volume0.68 Prev Close33.94
Employees493 LT Debt/Eq1.12 EarningsAug 07 BMO SMA2005.28% Avg Volume310.83K Price33.57
IPOFeb 05, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-45.77% 6.26% Trades Volume212,270 Change-1.09%
Date Action Analyst Rating Change Price Target Change
Sep-18-25Resumed Guggenheim Neutral
Aug-25-25Resumed Jefferies Buy $48
May-27-25Initiated Deutsche Bank Buy $65
Dec-13-24Downgrade Morgan Stanley Overweight → Equal-Weight $74 → $35
Nov-11-24Downgrade Mizuho Outperform → Neutral $72 → $38
Oct-24-24Initiated UBS Sell $24
Oct-07-24Downgrade Guggenheim Buy → Neutral
Apr-29-24Initiated Leerink Partners Outperform $74
Nov-20-23Resumed JP Morgan Overweight $60
Nov-02-23Initiated Cantor Fitzgerald Overweight
Oct-20-25 11:08PM
Sep-04-25 07:00AM
Aug-08-25 12:47PM
11:45AM
11:19AM
11:01AM Loading…
11:01AM
10:26AM
Aug-07-25 11:20AM
11:00AM
10:08AM
10:04AM
09:30AM
08:17AM
07:00AM
Aug-06-25 12:16PM
11:57AM Loading…
11:57AM
11:51AM
11:48AM
11:43AM
11:42AM
11:07AM
09:22AM
Aug-05-25 12:21PM
12:12PM
11:54AM
11:36AM
11:33AM
10:17AM
08:59AM
Aug-01-25 12:04PM
11:49AM Loading…
11:49AM
Jul-31-25 10:37AM
10:15AM
02:00AM
Jul-30-25 10:23AM
Jul-24-25 09:55AM
Jul-08-25 10:54AM
10:38AM
Jul-03-25 10:32AM
Jul-02-25 10:32AM
09:28AM
Jul-01-25 10:50AM
Jun-30-25 11:40AM
08:00AM
Jun-25-25 11:17AM
11:14AM
11:06AM
10:02AM
Jun-24-25 11:58AM
09:04AM
Jun-23-25 11:25AM
09:53AM
09:15AM
Jun-20-25 11:51AM
Jun-17-25 12:08PM
12:02PM
10:30AM
Jun-16-25 08:45AM
Jun-05-25 10:03AM
Jun-03-25 11:53AM
11:41AM
Jun-02-25 09:55AM
07:00AM
May-23-25 09:29AM
May-16-25 09:55AM
May-09-25 08:48AM
May-08-25 07:31AM
May-07-25 12:09PM
09:30AM
08:59AM
07:40AM
07:00AM
May-06-25 01:12PM
11:59AM
09:39AM
May-02-25 11:10AM
07:53AM
Apr-30-25 09:55AM
09:07AM
Apr-27-25 09:22AM
Apr-02-25 11:49AM
08:00AM
Mar-25-25 10:46AM
Mar-21-25 10:21AM
Mar-10-25 03:00PM
Mar-03-25 07:00AM
Feb-27-25 02:07AM
02:02AM
Feb-26-25 07:00AM
Feb-25-25 10:32AM
Feb-20-25 03:00AM
Feb-19-25 07:00AM
Jan-13-25 09:55AM
Jan-10-25 07:00AM
Jan-06-25 07:00AM
Jan-02-25 07:00AM
Dec-23-24 07:00AM
Dec-18-24 11:34AM
Dec-17-24 07:00AM
Dec-13-24 02:10PM
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berman David MHEAD OF R&DSep 30 '25Option Exercise17.4661,8491,079,88461,849Oct 02 04:10 PM
Berman David MHEAD OF R&DSep 30 '25Sale35.2361,8492,178,9400Oct 02 04:10 PM
Berman David MHEAD OF R&DSep 12 '25Option Exercise17.4622,532393,40922,532Sep 16 04:15 PM
Berman David MHEAD OF R&DSep 15 '25Option Exercise17.462003,492200Sep 16 04:15 PM
Berman David MHEAD OF R&DSep 12 '25Sale35.6722,532803,6990Sep 16 04:15 PM
Berman David MHEAD OF R&DSep 15 '25Sale35.012007,0020Sep 16 04:15 PM
Berman David MHEAD OF R&DSep 10 '25Option Exercise17.4631,338547,16131,338Sep 12 04:10 PM
Berman David MHEAD OF R&DSep 11 '25Option Exercise17.4619,081333,15419,081Sep 12 04:10 PM
Berman David MHEAD OF R&DSep 10 '25Sale36.1431,3381,132,7090Sep 12 04:10 PM
Berman David MHEAD OF R&DSep 11 '25Sale36.2819,081692,2590Sep 12 04:10 PM
David M. BermanOfficerSep 10 '25Proposed Sale36.59135,0004,939,650Sep 10 04:35 PM
BAKER BROS. ADVISORS LPDirectorMar 17 '25Buy29.72807,33823,993,2242,144,060Mar 19 06:40 PM
Brian Di DonatoaffiliateMar 17 '25Proposed Sale30.00100,0003,000,000Mar 17 04:24 PM
Brian Di DonatoaffiliateMar 14 '25Proposed Sale29.1356,2501,638,511Mar 14 05:08 PM